DOCSLIB.ORG

Billing and Coding Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Billing and Coding Guide INDICATION appear to be uncommon. These events were reported primarily among pediatric patients. The contribution of Rapivab to these events has not been established. Patients with RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 2 years influenza should be closely monitored for signs of abnormal behavior. and older who have been symptomatic for no more than 2 days. • Serious bacterial infections may begin with influenza-like symptoms or may coexist with IMPORTANT SAFETY INFORMATION or occur as complications during the course of influenza. Rapivab has not been shown to prevent such complications. LIMITATIONS OF USE ADVERSE REACTIONS • Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which The most common adverse reaction in adults (18 years of age and older) was diarrhea (8% the predominant influenza infections were influenza A virus; a limited number of subjects Rapivab vs 7% placebo). Lab abnormalities (incidence ≥2%) occurring more commonly with infected with influenza B virus were enrolled. Rapivab than placebo were elevated ALT 2.5 times the upper limit of normal (3% vs 2%), • Influenza viruses change over time. Emergence of resistance substitutions could decrease elevated serum glucose >160 mg/dL (5% vs 3%), elevated CPK at least 6 times the upper limit drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish of normal (4% vs 2%), and neutrophils <1.0 x 109/L (8% vs 6%). In a subset of subjects with clinical benefit of antiviral drugs. Prescribers should consider available information on serious influenza requiring hospitalization treated with RAPIVAB 600 mg as monotherapy influenza drug susceptibility patterns and treatment effects when deciding whether to use (N=101), the following adverse reactions were also reported more frequently with RAPIVAB as RAPIVAB. compared to placebo: constipation (4% versus 2%), insomnia (3% versus 0%), AST increased • The efficacy of RAPIVAB could not be established in patients with serious influenza requiring (3% versus 2%), and hypertension (2% versus 0%). hospitalization. The safety profile of RAPIVAB in subjects 2 to 17 years of age was generally similar to that observed in adults. Specific adverse reactions reported in pediatric subjects treated CONTRAINDICATIONS with RAPIVAB (occurring in ≥2% of subjects) and not reported in adults included vomiting RAPIVAB is contraindicated in patients with known serious hypersensitivity or anaphylaxis (3% versus 9% for oseltamivir), fever and tympanic membrane erythema (2% versus 0%, to peramivir or any component of the product. Severe allergic reactions have included respectively, for each of these events). The only clinically significant laboratory abnormality anaphylaxis, erythema multiforme and Stevens-Johnson Syndrome. (DAIDS Grade 2) occurring in ≥2% of pediatric subjects treated with RAPIVAB was proteinuria by dipstick analysis (3% versus 0% for oseltamivir). WARNINGS AND PRECAUTIONS • Rare cases of serious skin reactions, including erythema multiforme, have been reported CONCURRENT USE WITH LIVE ATTENUATED INFLUENZA VACCINE with RAPIVAB in clinical studies and in postmarketing experience. Cases of anaphylaxis Antiviral drugs may inhibit viral replication of a live attenuated influenza vaccine (LAIV) and and Stevens-Johnson Syndrome have been reported in postmarketing experience with thus may reduce vaccine efficacy). The concurrent use of Rapivab with LAIV intranasal has RAPIVAB. Discontinue RAPIVAB and institute appropriate treatment if anaphylaxis or a not been evaluated. Because of the potential for interference between these two products, serious skin reaction occurs or is suspected. The use of RAPIVAB is contraindicated in avoid use of Rapivab within 2 weeks after or 48 hours before administration of LAIV unless patients with known serious hypersensitivity or anaphylaxis to RAPIVAB. medically indicated. • Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some Please see accompanying full Prescribing Information for RAPIVAB. cases resulting in fatal outcomes. There have been postmarketing reports of delirium You are encouraged to report negative side effects of prescription drugs to the FDA. and abnormal behavior leading to injury in patients with influenza who were receiving Visit www.fda.gov/medwatch or call 1-800-FDA-1088. neuraminidase inhibitors, including Rapivab. Because these events were reported RAPIVAB is a registered trademark of Seqirus UK Limited or its affiliates. voluntarily during clinical practice, estimates of frequency cannot be made, but they 13 and accompanying full Prescribing Information. Prescribing full accompanying and October 2019 US/CORP/1016/0004(5) 2019 October 25 Deforest Ave, Summit NJ 07901 NJ Summit Ave, Deforest 25 Please see Important Safety Information on pages 6-8 and 13, 13, and 6-8 pages on Information Safety Important see Please © 2019 Seqirus USA Inc. All rights reserved. rights All Inc. USA Seqirus 2019 © are registered trademarks of Seqirus UK Limited or its affiliates. its or Limited UK Seqirus of trademarks registered are RAPIVAB and QUADRIVALENT, FLUCELVAX FLUAD, QUADRIVALENT, AFLURIA Services website. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/r167cp.pdf. website. Services Accessed October 23, 2019. 23, October Accessed 2004. 30, April Published 13. CMS manual system. Publication 100-04 Medicare claims processing. Centers for Medicare and Medicaid Medicaid and Medicare for Centers processing. claims Medicare 100-04 Publication system. manual CMS 2019. 23, October Accessed 2015. April Published CHEST%20Physician/Vol%2010%202015/0415.ashx. 12. 12. Nelson ME. ICD-10 cometh. CHEST Physician website. http://www.chestnet.org/~/media/chesnetorg/Publications/Documents/ website. Physician CHEST cometh. ICD-10 ME. Nelson 2019. 23, October Accessed 2017. Published Reimbursement-Coding-Update-2017.pdf. 11. Parman C. Oncology reimbursement coding update. 2017. Association of Community Cancer Centers website. https://www.accc-cancer.org/publications/pdf/Oncology- website. Centers Cancer Community of Association 2017. update. coding reimbursement Oncology C. Parman 2018. Inc; USA Seqirus NJ: Summit, insert]. 10. 10. diseases and injuries. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2018-ICD-10-Table-And-Index.zip. Accessed October 23, 2019. 2019. 23, October Accessed https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2018-ICD-10-Table-And-Index.zip. website. Services Medicaid and Medicare for Centers injuries. and diseases Rapivab [package [package Rapivab 9. 9. website. https://www.acep.org/administration/reimbursement/ed-facility-level-coding-guidelines/#sm.000005vd05555heczqbvu9txsrjf3. Published 2011. Accessed October 23, 2019. 2019. 23, October Accessed 2011. Published https://www.acep.org/administration/reimbursement/ed-facility-level-coding-guidelines/#sm.000005vd05555heczqbvu9txsrjf3. website. ICD-10-CM tabular list of of list tabular ICD-10-CM 7. 7. 8. 8. Procedural Coding Expert: The Ultimate Guide to CPT to Guide Ultimate The Expert: Coding Procedural 2019. 23, October Accessed ED facility level coding guidelines. American College of Emergency Physicians Physicians Emergency of College American guidelines. coding level facility ED 2012. Media; Contexo UT: City, Lake Salt Coding. ® hepatitis B. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/qr_immun_bill.pdf. Published January 2018. 2018. January Published https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/qr_immun_bill.pdf. website. Services Medicaid and Medicare for Centers B. hepatitis 6. 6. Pediatrics website. https://www.aap.org/en-us/Documents/coding_preventive_care.pdf. Published 2019. Accessed October 23, 2019. 2019. 23, October Accessed 2019. Published https://www.aap.org/en-us/Documents/coding_preventive_care.pdf. website. Pediatrics Medicare part B immunization billing: seasonal influenza virus, pneumococcal, and and pneumococcal, virus, influenza seasonal billing: immunization B part Medicare 5. 5. 4. 3. FLUCELVAX QUADRIVALENT [package insert]. Summit, NJ: Seqirus USA Inc; 2019. 2019. Inc; USA Seqirus NJ: Summit, insert]. [package QUADRIVALENT FLUCELVAX 2019. Inc; USA Seqirus NJ: Summit, insert]. [package FLUAD Coding for pediatric preventive care, 2018. American Academy of of Academy American 2018. care, preventive pediatric for Coding 2. 1. References: Afluria Quadrivalent [package insert]. Summit, NJ: Seqirus USA Inc; 2019. 2019. Inc; USA Seqirus NJ: Summit, insert]. [package Quadrivalent Afluria http://www.immunize.org. website. Coalition Action Immunization season. influenza 2019-2020 for products vaccine Influenza INFLUENZA SEASON INFLUENZA 2019-2020 CODING GUIDE CODING #3 OPTION 855-358-8966, CALL SUPPORT REIMBURSEMENT FOR treatment and BILLING AND BILLING @seqirus.com of influenza vaccines influenza of customerservice.us about our portfolio portfolio our about flu.seqirus.com service at at service account manager manager account Email customer customer Email at online Order Contact your Seqirus Seqirus your Contact 3 EASY ORDERING METHODS: ORDERING EASY 3 This influenza season, count on the Seqirus the on count season, influenza This portfolio of influenza products.
Load more

Recommended publications
  • November 5, 2003 – Letter to the Secretary – Comments on CHI
    November 5, 2003 The Honorable Tommy G. Thompson Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, D.C. 20201 Dear Secretary Thompson: The National Committee on Vital and Health Statistics (NCVHS) commends you for your commitment toward government wide adoption of clinical data standards that you first announced on March 21, 2003. NCVHS recognizes and appreciates that there is new momentum to adopt clinical data standards that is driven by you and the Consolidated Healthcare Informatics Initiative (CHI). Consequently, NCVHS is now working closely with CHI to study, select and recommend domain specific patient medical record information (PMRI) terminology standards. We have mutually developed a process that allows NCVHS to discuss in open, interactive sessions CHI recommendations as part of the CHI Council acceptance process. The NCVHS has the following comments on the attached set of CHI domain area recommendations: • The NCVHS concurs with the CHI recommendations for Interventions and Procedures: Part B, Laboratory Test Order Names. • The NCVHS concurs with the CHI recommendations for the Medication Domain as modified in the attached document. We further note: o the need for additional funding for the Food and Drug Administration (FDA) to expedite the publication of a publicly available version of their Unique Ingredient Identifier (UNII) codes and to provide continued funding to maintain the UNII code standard; o that the dosage and administration sub-domain be investigated in the next phase of the CHI process; and o that the FDA National Drug Code (NDC) process be investigated and improvements identified be expeditiously pursued. • The NCVHS concurs with the CHI recommendations for the Immunization Domain as modified in the attached document.
    [Show full text]
  • Ata Lements for Mergency Epartment Ystems
    D ata E lements for E mergency D epartment S ystems Release 1.0 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CDCCENTERS FOR DISEASE CONTROL AND PREVENTION D ata E lements for E mergency D epartment S ystems Release 1.0 National Center for Injury Prevention and Control Atlanta, Georgia 1997 Data Elements for Emergency Department Systems, Release 1.0 (DEEDS) is the result of contributions by participants in the National Workshop on Emergency Department Data, held January 23-25, 1996, in Atlanta, Georgia, subsequent review and comment by individuals who read Release 1.0 in draft form, and finalization by a multidisciplinary writing committee. DEEDS is a set of recommendations published by the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention: Centers for Disease Control and Prevention David Satcher, MD, PhD, Director National Center for Injury Prevention and Control Mark L. Rosenberg, MD, MPP, Director Division of Acute Care, Rehabilitation Research, and Disability Prevention Richard J. Waxweiler, PhD, Director Acute Care Team Daniel A. Pollock, MD, Leader Production services were provided by the staff of the Office of Communication Resources, National Center for Injury Prevention and Control, and the Management Analysis and Services Office: Editing Valerie R. Johnson Cover Design and Layout Barbara B. Lord Use of trade names is for identification only and does not constitute endorsement by the U.S. Department of Health and Human Services. This document and subsequent revisions can be found at the National Center for Injury Prevention and Control Web site: http://www.cdc.gov/ncipc/pub-res/deedspage.htm Suggested Citation: National Center for Injury Prevention and Control.
    [Show full text]
  • (USCDI), Version 1, July 2020 Errata
    Allergies and Intolerances .... 5 The USCDI is a standardized Assessment and Plan of set of health data classes and Treatment ............................ 5 Care Team Member(s) ......... 6 constituent data elements for Clinical Notes ........................ 7 nationwide, interoperable Goals ..................................... 8 Health Concerns ................... 8 health information exchange. Immunizations ...................... 9 Laboratory ............................ 9 A USCDI “Data Class” is an aggregation of various Data Elements by a common theme or use case. Medications ........................ 10 Patient Demographics ........ 10 A USCDI “Data Element” is the most granular level Problems ............................ 12 at which a piece of data is represented in the USCDI Procedures ......................... 12 for exchange. Provenance ........................ 13 Smoking Status ................... 13 Unique Device Identifier(s) for a Patient’s Implantable Device(s) ............................. 13 Vital Signs ........................... 14 2 Version History Version # Description of change Version Date 1 First Publication February 2020 1 (July 2020 Corrections to Applicable Standards July 2020 Errata) • Substance (Medication) - Removed UCUM • Patient’s Goals, Health Concerns, Assessment and Plan of Treatment - Removed LOINC, SNOMED CT • Laboratory Tests, Values/Results - Removed SNOMED CT and UCUM • Medications - Removed UCUM 3 USCDI v1 Summary of Data Classes and Data Elements Allergies and Intolerances Laboratory Smoking Status
    [Show full text]
  • Report-Health Terminologies and Vocabularies Environmental Scan
    Health Terminologies and Vocabularies Environmental Scan Conducted for the National Committee on Vital and Health Statistics Subcommittee on Standards September 14, 2018 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Terminologies and Vocabularies Environmental Scan NCVHS Subcommittee on Standards This report was written by Susan L. Roy, MS, MLS, SNOMED CT Coordinator, and Vivian A. Auld, MLIS, Senior Specialist for Health Data Standards, both with the National Institutes of Health (NIH), National Library of Medicine, in collaboration with the NCVHS Standards Subcommittee: NCVHS Membership William W. Stead, MD, NCVHS Chair Nicholas L. Coussoule,* Subcommittee Co-chair Alexandra Goss,* Subcommittee Co-chair Bruce B. Cohen, PhD David A. Ross, ScD Debra Strickland, MS* Denise E. Love, BSN, MBA* Jacki Monson, JD Linda L. Kloss, MA, RHIA*, Terminology and Vocabulary Project Lead Llewellyn J. Cornelius, PhD Richard W. Landen, MPH, MBA* Robert L. Phillips, Jr., MD, MSPH Roland J. Thorpe, Jr., PhD Vickie M. Mays, PhD, MSPH *Member of the Subcommittee on Standards Rebecca Hines, MHS, NCVHS Executive Secretary/DFO Health Scientist National Center for Health Statistics, CDC, HHS Rashida Dorsey, PhD, MPH, NCVHS Executive Staff Director Director, Division of Data Policy Senior Advisor on Minority Health and Health Disparities Office of Science and Data Policy Office of the Assistant Secretary for Planning and Evaluation, HHS The National Committee on Vital and Health Statistics (NCVHS) serves as the advisory committee to the Secretary of Health and Human Services (HHS) on health data, statistics, privacy, national health information policy, and the Health Insurance Portability and Accountability Act (HIPAA) (42U.S.C.242k[k]).
    [Show full text]
  • (Child Core Set) Technical Specifications and Reso
    Core Set of Children's Health Care Quality Measures for Medicaid and CHIP (Child Core Set) Technical Specifications and Resource Manual for Federal Fiscal Year 2019 Reporting February 2019 Center for Medicaid and CHIP Services Centers for Medicare & Medicaid Services This page left blank for double-sided copying ii ACKNOWLEDGMENTS For Proprietary Codes: CPT® codes copyright 2018 American Medical Association. All rights reserved. CPT is a trademark of the American Medical Association. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2018 The International Health Terminology Standards Development Organisation. All Rights Reserved. The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) is published by the World Health Organization (WHO). ICD-9-CM is an official Health Insurance Portability and Accountability Act standard. The International Classification of Diseases, 9th Revision, Procedure Coding System (ICD-9-PCS) is published by the World Health Organization (WHO). ICD-9-PCS is an official Health Insurance Portability and Accountability Act standard. The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) is published by the World Health Organization (WHO). ICD-10-CM is an official Health Insurance Portability and Accountability Act standard. The International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) is published by the World Health Organization (WHO). ICD-10-PCS is an official Health Insurance Portability and Accountability Act standard. This material contains content from LOINC® (http://loinc.org).
    [Show full text]
  • Billing and Coding Considerations for BLINCYTO®
    BLINCYTO® Billing Information Sheet Billing and Coding Considerations for BLINCYTO® This Information Sheet is intended to help healthcare professionals understand the key billing and coding considerations for BLINCYTO® and its related services and supplies when using the FDA-approved dosing options in inpatient and outpatient treatment settings. Updates for 2018 include: • Information on billing the 7-day infusion option (7-DIO) in addition to the shorter-duration 24-hour and 48-hour bags BLINCYTO® Dosing Options1 Dose per vial X number of Dosing option Number of billing units single-dose vials (SDVs*) 24-hour 35 mcg X 1 vial 35 48-hour 35 mcg X 1-2 vials 35-70 7-day 35 mcg X 4-6 vials 140-210 • New coding requirement for BLINCYTO® administered in the outpatient setting of 340B hospitals – The Centers for Medicare & Medicaid Services (CMS) requires use of new modifiers on Medicare claims for drugs acquired under the 340B Drug Discount Program2 • Medicare patients receiving BLINCYTO® in the inpatient setting are no longer eligible for additional reimbursement3 – The new technology add-on payment (NTAP) designation has been retired; hospitals may still be eligible for outlier payments based on payer guidance and managed care contract provisions *Number of SDVs depends on dose, infusion duration, and patient's weight.1 Please note that the information in this resource is intended to be educational and is not a guarantee of reimbursement. Coverage, coding, and billing requirements vary by health plan so be sure to check with individual payers for detailed guidance. Indications BLINCYTO® is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.
    [Show full text]
  • The Role of Family Practice in Different Health Care Systems
    January 2002 · Vol. 51, No. 1 JFP ONLINE The Role of Family Practice in Different Health Care Systems A Comparison of Reasons for Encounter, Diagnoses, and Interventions in Primary Care Populations in the Netherlands, Japan, Poland, and the United States I.M. Okkes, MA, PhD; G.O. Polderman, MD; G.E. Fryer, PhD; T. Yamada, MD; M. Bujak, MD; S.K. Oskam, MSc, PhD; L.A. Green, MD; H. Lamberts, MD, PhD Amsterdam and Amstelveen, the Netherlands; Tokyo, Japan; Katowice, Poland; and Washington, DC Submitted, revised, October 21, 2001. From the Academic Medical Center/University of Amsterdam, Division of Public Health, Department of Family Practice, Amsterdam (I.M.O., S.K.O., H.L.); Family Physician, Transition Project, Amstelveen (G.O.P.); the Robert Graham Center: Policy Studies in Family Practice and Primary Care, Washington, DC (G.E.F., L.A.G.); the Japanese Association for Development of Community Medicine, Tokyo (T.Y.); and the Silesian Medical School, Katowice (M.B.). Reprint requests should be addressed to I.M. Okkes, MA, PhD, Academic Medical Center/University of Amsterdam, Division Public Health, Department of Family Practice, Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands. E-mail: [email protected]. z OBJECTIVE: Our goal was to compare the content of family practice in different countries using databases containing information on reasons for encounter, diagnoses, and interventions that are coded with or can be addressed by the International Classification of Primary Care (ICPC). z STUDY DESIGN: In the Netherlands, Japan, and Poland data were collected identically with an electronic patient record (Transhis).
    [Show full text]
  • 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes
    2018 ANNUAL SURVEILLANCE REPORT OF DRUG-RELATED RISKS AND OUTCOMES UNITED STATES Centers for Disease Control and Prevention National Center for Injury Prevention and Control Annual Surveillance Report of Drug-Related Risks and Outcomes | United States CDC National Center for Injury Prevention and Control | 2018 ACKNOWLEDGEMENTS This Surveillance Report was prepared by staff from the National Disclaimer Center for Injury Prevention and Control (NCIPC), Centers for Disease The findings and conclusions in Control and Prevention (CDC), U.S. Department of Health and Human this report are those of the authors Services, Atlanta, Georgia. and do not necessarily represent the views of the Centers for Disease Control and Prevention. This Contributors to this report included: Brooke E. Hoots, PhD, MSPH1, 2 3 research was supported in part by Likang Xu, MD, MS , Mbabazi Kariisa, PhD , Nana Otoo Wilson, PhD, an appointment to the Research 1 1 1,4 MPH, MSc , Rose A. Rudd, MSPH , Lawrence Scholl, PhD, MPH , Lyna Participation Program at the Centers 1 1 Schieber, MD, DPhil , and Puja Seth, PhD for Disease Control and Prevention 1Division of Unintentional Injury Prevention (DUIP), National Center for administered by the Oak Ridge Injury Prevention and Control, CDC Institute for Science and Education 2Division of Analysis, Research, and Practice Integration (DARPI), through an interagency agreement National Center for Injury Prevention and Control, CDC between the U.S. Department of 3Oak Ridge Institute for Science and Education, Oak Ridge, TN Energy and CDC. 4Epidemic Intelligence Service, CDC All material in this report is in the public domain and may be used Corresponding authors: Brooke E.
    [Show full text]
  • 보건의료정보 표준화 연구 Research of Health Information Standardization
    보안과제( ), 일반과제( o ) A040165 보건의료기술연구개발(의료정보기술개발) 보건의료정보 표준화 연구 Research of Health Information Standardization 한국보건산업진흥원 한국보건산업진흥원 제 출 문 보건복지부 장관 귀하 이 보고서를 “보건의료정보 표준화 연구(고유번호 : 0412-MI02-0416-0001)” 과제의 최종보고서로 제출합니다. 2005 . 6 . 30 주관연구기관 : 한국보건산업진흥원 직인 주관연구책임자 : 공 재 근 직인 ❀ 보건의료정보 표준화에 참여해 주신 분들 ❀ 표준화위원회 •위원장 : 김 윤(서울의대 의료관리학교실) •표준화위원 서창해(인하의대 방사선과) 이영종(경원대 한의대) 감 신(경북의대 예방의학교실) 최행정(국민건강보험공단 일산병원 의무기록팀) 박현애(서울대 간호대) 김석일(가톨릭의대 예방의학교실) 김옥남(서울아산중앙병원 의무기록팀) 신형식(라이프엠) 황 건(인하대병원 성형외과) 이태한(보건복지부 혁신인사기획관) 이갑노(고려대 진단검사의학과) 임종규(보건복지부 보건의료서비스산업육성팀) 이숙향(숙명여대 임상약학대학원) 선우종성(보건복지부 정보화담당관실) 김보연(건강보험심사평가원 급여관리실) 박민수(보건복지부 공공보건정책과) 자문위원회 •위원장 : 곽연식 •자문위원 채영문(연세대 보건대학원) 윤순녕(서울대 간호대) 김명기(서울대 치과의료관리학과) 신현택(숙명여대 약학대학) 지제근(서울의대 병리과) 염용권(한국보건산업진흥원 보건의료기술연구 사업관리본부) 기획위원회 •위원장 : 김 윤(서울의대 의료관리학교실) •기획위원 박현애(서울대 간호대) 김곤희(보건복지부 공공보건정책과) 김석일(가톨릭의대 예방의학교실) 좌용권(한국보건산업진흥원) 신형식(라이프엠) 부유경(인하대병원 의료정보과) 김소윤(보건복지부 보건의료서비스산업육성팀) 박경모(경희대 동서의료공학과) 기획위원회 지원 이관익(한국보건산업진흥원) 곽미숙(서울대의대 의료관리학교실) 박정선(한국보건산업진흥원) 손수인(한국보건산업진흥원) 구현경(서울대의대 의료관리학교실) - 3 - 의료용어분과위원회 •분과위원장 : 서창해(인하대 의대 방사선과학) •분과위원 부유경(인하대병원 의료정보과) 김대성(한진정보통신) 최선근(인하의대 외과) 심진수(한진정보통신) 이연숙(인하대병원 전산정보팀) •자문위원 진호준(서울대 분당병원 내과) 김지영(분당재생병원 의무기록과) 최진욱(서울대 의용공학과) 유연순(이대목동병원 의무기록과) 박찬병(수원의료원) 서진숙(삼성서울병원 의무기록파트) 박덕영(강릉대학교 예방치학교실) 강재은(서울대 분당병원 의무기록파트) 서순원(단국대병원 의무기록과) 이은미(신촌세브란스병원 의무기록과) 최행정(건강보험공단일산병원 의무기록팀) 김란혜(경희의료원 의무기록과) 김옥남(서울아산병원 의무기록팀) 보건용어분과위원회 •분과위원장 : 감신(경북대의대 예방의학교실) •분과위원 이은미(신촌세브란스병원 의무기록과) 진대구(대구 성서병원) 이중정(계명대학교 의과대학) 정은경(질병관리본부) 이원영(중앙대학교 의과대학) 이상원(대구카톨릭대학교 의과대학) 황태윤(영남대학교 의과대학) 김찬호(경기도 안양시 보건소) 이인숙(서울대학교 간호대학)
    [Show full text]
  • Coding Basics
    Coding Basics 60889-R5-V1 • This information is provided for your background education and is not intended to serve as guidance for specific coding, billing, and claims submissions. The decision on which codes best describe the services provided must be made by the individual providers based on specific payor guidance and requirements. 2 Agenda • Define each code set – HCPCS – CPT® – NDC – ICD-9-CM – ICD-10-CM • Discuss general formats • Apply coding basics to sample claim forms – Physician office setting (CMS-1500 claim form) – Hospital outpatient setting (UB-04 claim form) CPT is a registered trademark of the American Medical Association. All rights reserved. 3 Healthcare Common Procedure Coding System (HCPCS)1 HCPCS codes describe products, supplies, items and services not included in CPT They establish a standard coding system that allow claims to be processed in a consistent manner The use of the HCPCS is mandatory • It is alpha-numeric. The format is a single alphabetical letter (A to V) followed by 4 numeric digits • Maintained by Centers for Medicare and Medicaid Services (CMS) 1. Centers for Medicare & Medicaid Services (CMS), New CMS Coding Changes Will Help Beneficiaries. https://www.cms.gov/MedHCPCSGenInfo/Downloads/HCPCSReform.pdf. Accessed January 30, 2012. 4 Current Procedural Terminology (CPT)1 Developed by the American Medical Association (AMA), it is a list of descriptive terms that identify medical services and procedures It allows for communication of uniform information among physicians, coders, patients, and payers Category I CPT codes •Describe a procedure or service identified with a 5-digit code and descriptor nomenclature Category II CPT Codes •Supplemental tracking codes that can be used for performance measurement (optional) Category III CPT Codes •Temporary set of tracking codes for new and emerging technologies intended to facilitate data collection on and assessment of new services and procedures 1.
    [Show full text]
  • Who Gets Medication-Assisted Treatment for Opioid Use Disorder, and Does It Reduce Overdose Risk? Evidence from the Rhode Island All-Payer Claims Database Mary A
    No. 21-3 Who Gets Medication-assisted Treatment for Opioid Use Disorder, and Does It Reduce Overdose Risk? Evidence from the Rhode Island All-payer Claims Database Mary A. Burke, Riley Sullivan, Katherine Carman, Hefei Wen, J. Frank Wharam, and Hao Yu Abstract: This paper uses the all-payer claims database (APCD) for Rhode Island to study three questions about the use of medication-assisted treatment (MAT) for opioid use disorder (OUD): (1) Does MAT reduce the risk of opioid overdose; (2) are there systematic differences in the uptake of MAT by observable patient-level characteristics; and (3) how successful were federal policy changes implemented in 2016 that sought to promote increased use of buprenorphine, one of three medication options within MAT? Regarding the first question, we find that MAT as practiced in Rhode Island is associated with a reduced risk of repeated opioid overdose among patients who had an initial nonfatal opioid overdose, consistent with the strong endorsement of MAT by public health officials. Concerning the second, we find that factors such as age, gender, health insurance payer, and the poverty rate in one’s residential Zip code are associated with significant differences in the chance of receiving methadone and/or buprenorphine, suggesting that certain groups may face unwarranted disparities in access to MAT. About the third question, we find that a 2016 federal rule change enabled at least some experienced Rhode Island buprenorphine prescribers to reach more patients, and a separate 2016 policy aimed at recruiting new buprenorphine prescribers was also found to be effective. However, the data also suggest that many more patients in the state could be treated with buprenorphine if prescribers took full advantage of their prescribing limits.
    [Show full text]
  • Common Semantic Strategy for Health in the European Union WP8 Integration in National Policies and Sustainability Draft
    D8.2.2 Common Semantic Strategy for Health in the European Union WP8 Integration in National Policies and Sustainability Draft Revision 1.4, 10-05-2019 15th eHN meeting, June 2019 For Discussion Grant Agreement nº 801558 D8.2.2 Common Semantic Strategy WP8 Integration in National Policies and Sustainability Draft for Discussion Revision 1.4, 10-05-2019 CONTROL PAGE OF DOCUMENT Document name CSS for Health in the EU – Information paper for eHN Status Draft Author(s) Country Organisation Name Austria Sozial Ministerium Peter Brosch Croatia HZZO Vesna Kronstein Kufrin Czech Republic MoH Czech Republic Hynek Kruzik Estonia HWISC Kerli Linna Finland THL Mikko Härkönen Germany DIMDI Stefanie Weber Hungary AEEK Gergely Heja Eamon Coyne; Ireland HSE Theresa Barry Lithuania LMB Martynas Bieliauskas Netherlands NICTIZ Pim Volkert Norway EHELSE Jostein Vein MoH Poland Hubert Zycinski; Poland CZIOZ Ania Ostrowicka Henrique Martins; Diogo Martins; Jurgen Wehnert; Lilia Marques; Cristiana Antunes; Filipa Rasquinho; Portugal SPMS Daniela Costa; Filipe Mealha; Joana Cunha; Carla Pereira; Anabela Santos; Anderson do Carmo Slovenia NIJZ Lucija Tepej-Jocic Arturo Romero Gutiérrez; Spain MoH Spain Miguel Pedrera Jiménez Sweden Socialstyrelsen Daniel Karlsson 2/31 eHAction – Joint Action supporting the eHealth Network - www.ehaction.eu D8.2.2 Common Semantic Strategy WP8 Integration in National Policies and Sustainability Draft for Discussion Revision 1.4, 10-05-2019 REVISION HISTORY Revision Date Author Description Daniel Karlsson; Stefanie Weber; Mikko Härkönen; Vesna Kronstein Kufrin; Hynek st 0.1 11/02/2019 Kruzik; Hubert Zycinski; Kerli Linna 1 draft document Input of new content. 0.2 25/02/2019 Carla Pereira; Daniela Costa; Lucija Tepej-jocic Comments on the Document 0.3 05/03/2019 Arturo Romero; Jurgen Wehnert Comments on the Document Peter Brosch; Hynek Kruzik;Daniel Karlsson; Input of new content.
    [Show full text]